Selected research
Industry Research
Gastric Inhibitory Polypeptide Receptor Industry Research Report 2026
Market perspective
The global Gastric Inhibitory Polypeptide Receptor market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Gastric Inhibitory Polypeptide Receptor is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Gastric Inhibitory Polypeptide Receptor is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Gastric Inhibitory Polypeptide Receptor is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Gastric Inhibitory Polypeptide Receptor include Sanofi, Novo Nordisk A/S, AstraZeneca Plc, Zealand Pharma A/S, Longevity Biotech, Inc, Diabetica Limited, Carmot Therapeutics, Inc. and Alchemia Limited, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Gastric Inhibitory Polypeptide Receptor market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Gastric Inhibitory Polypeptide Receptor Market by Company
Sanofi
Novo Nordisk A/S
AstraZeneca Plc
Zealand Pharma A/S
Longevity Biotech, Inc
Diabetica Limited
Carmot Therapeutics, Inc.
Alchemia Limited
Gastric Inhibitory Polypeptide Receptor Segment by Type
HM-15211
LBT-6030
LY-3298176
NNC-92041706
Others
Gastric Inhibitory Polypeptide Receptor Segment by Application
Obesity
Metabolic Disorder
Type 2 Diabetes
Others
Gastric Inhibitory Polypeptide Receptor Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gastric Inhibitory Polypeptide Receptor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gastric Inhibitory Polypeptide Receptor and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gastric Inhibitory Polypeptide Receptor.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Gastric Inhibitory Polypeptide Receptor manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Gastric Inhibitory Polypeptide Receptor by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Gastric Inhibitory Polypeptide Receptor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- HM-15211
- LBT-6030
- LY-3298176
- NNC-92041706
- Others
Applications
- Obesity
- Metabolic Disorder
- Type 2 Diabetes
- Others
Companies covered
- Sanofi
- Novo Nordisk A/S
- AstraZeneca Plc
- Zealand Pharma A/S
- Longevity Biotech, Inc
- Diabetica Limited
- Carmot Therapeutics, Inc.
- Alchemia Limited
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Gastric Inhibitory Polypeptide Receptor Market Size (2021-2032)
- 2.2.2 Global Gastric Inhibitory Polypeptide Receptor Sales (2021-2032)
- 2.2.3 Global Gastric Inhibitory Polypeptide Receptor Market Average Price (2021-2032)
- 2.3 Gastric Inhibitory Polypeptide Receptor by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 HM-15211
- 2.3.3 LBT-6030
- 2.3.4 LY-3298176
- 2.3.5 NNC-92041706
- 2.3.6 Others
- 2.4 Gastric Inhibitory Polypeptide Receptor by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Obesity
- 2.4.3 Metabolic Disorder
- 2.4.4 Type 2 Diabetes
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Gastric Inhibitory Polypeptide Receptor Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Gastric Inhibitory Polypeptide Receptor Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Gastric Inhibitory Polypeptide Receptor Revenue of Manufacturers (2021-2026)
- 3.4 Global Gastric Inhibitory Polypeptide Receptor Average Price by Manufacturers (2021-2026)
- 3.5 Global Gastric Inhibitory Polypeptide Receptor Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Gastric Inhibitory Polypeptide Receptor, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Gastric Inhibitory Polypeptide Receptor, Product Type & Application
- 3.8 Global Manufacturers of Gastric Inhibitory Polypeptide Receptor, Established Date
- 3.9 Global Gastric Inhibitory Polypeptide Receptor Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Sanofi
- 4.1.1 Sanofi Company Information
- 4.1.2 Sanofi Business Overview
- 4.1.3 Sanofi Gastric Inhibitory Polypeptide Receptor Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Sanofi Gastric Inhibitory Polypeptide Receptor Product Portfolio
- 4.1.5 Sanofi Recent Developments
- 4.2 Novo Nordisk A/S
- 4.2.1 Novo Nordisk A/S Company Information
- 4.2.2 Novo Nordisk A/S Business Overview
- 4.2.3 Novo Nordisk A/S Gastric Inhibitory Polypeptide Receptor Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Novo Nordisk A/S Gastric Inhibitory Polypeptide Receptor Product Portfolio
- 4.2.5 Novo Nordisk A/S Recent Developments
- 4.3 AstraZeneca Plc
- 4.3.1 AstraZeneca Plc Company Information
- 4.3.2 AstraZeneca Plc Business Overview
- 4.3.3 AstraZeneca Plc Gastric Inhibitory Polypeptide Receptor Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 AstraZeneca Plc Gastric Inhibitory Polypeptide Receptor Product Portfolio
- 4.3.5 AstraZeneca Plc Recent Developments
- 4.4 Zealand Pharma A/S
- 4.4.1 Zealand Pharma A/S Company Information
- 4.4.2 Zealand Pharma A/S Business Overview
- 4.4.3 Zealand Pharma A/S Gastric Inhibitory Polypeptide Receptor Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Zealand Pharma A/S Gastric Inhibitory Polypeptide Receptor Product Portfolio
- 4.4.5 Zealand Pharma A/S Recent Developments
- 4.5 Longevity Biotech, Inc
- 4.5.1 Longevity Biotech, Inc Company Information
- 4.5.2 Longevity Biotech, Inc Business Overview
- 4.5.3 Longevity Biotech, Inc Gastric Inhibitory Polypeptide Receptor Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Longevity Biotech, Inc Gastric Inhibitory Polypeptide Receptor Product Portfolio
- 4.5.5 Longevity Biotech, Inc Recent Developments
- 4.6 Diabetica Limited
- 4.6.1 Diabetica Limited Company Information
- 4.6.2 Diabetica Limited Business Overview
- 4.6.3 Diabetica Limited Gastric Inhibitory Polypeptide Receptor Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Diabetica Limited Gastric Inhibitory Polypeptide Receptor Product Portfolio
- 4.6.5 Diabetica Limited Recent Developments
- 4.7 Carmot Therapeutics, Inc.
- 4.7.1 Carmot Therapeutics, Inc. Company Information
- 4.7.2 Carmot Therapeutics, Inc. Business Overview
- 4.7.3 Carmot Therapeutics, Inc. Gastric Inhibitory Polypeptide Receptor Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Carmot Therapeutics, Inc. Gastric Inhibitory Polypeptide Receptor Product Portfolio
- 4.7.5 Carmot Therapeutics, Inc. Recent Developments
- 4.8 Alchemia Limited
- 4.8.1 Alchemia Limited Company Information
- 4.8.2 Alchemia Limited Business Overview
- 4.8.3 Alchemia Limited Gastric Inhibitory Polypeptide Receptor Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Alchemia Limited Gastric Inhibitory Polypeptide Receptor Product Portfolio
- 4.8.5 Alchemia Limited Recent Developments
5 Global Gastric Inhibitory Polypeptide Receptor Market Scenario by Region
- 5.1 Global Gastric Inhibitory Polypeptide Receptor Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Gastric Inhibitory Polypeptide Receptor Sales by Region: 2021-2032
- 5.2.1 Global Gastric Inhibitory Polypeptide Receptor Sales by Region: 2021-2026
- 5.2.2 Global Gastric Inhibitory Polypeptide Receptor Sales by Region: 2027-2032
- 5.3 Global Gastric Inhibitory Polypeptide Receptor Revenue by Region: 2021-2032
- 5.3.1 Global Gastric Inhibitory Polypeptide Receptor Revenue by Region: 2021-2026
- 5.3.2 Global Gastric Inhibitory Polypeptide Receptor Revenue by Region: 2027-2032
- 5.4 North America Gastric Inhibitory Polypeptide Receptor Market Facts & Figures by Country
- 5.4.1 North America Gastric Inhibitory Polypeptide Receptor Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Gastric Inhibitory Polypeptide Receptor Sales by Country (2021-2032)
- 5.4.3 North America Gastric Inhibitory Polypeptide Receptor Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Gastric Inhibitory Polypeptide Receptor Market Facts & Figures by Country
- 5.5.1 Europe Gastric Inhibitory Polypeptide Receptor Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Gastric Inhibitory Polypeptide Receptor Sales by Country (2021-2032)
- 5.5.3 Europe Gastric Inhibitory Polypeptide Receptor Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Gastric Inhibitory Polypeptide Receptor Market Facts & Figures by Country
- 5.6.1 Asia Pacific Gastric Inhibitory Polypeptide Receptor Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Gastric Inhibitory Polypeptide Receptor Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Gastric Inhibitory Polypeptide Receptor Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Gastric Inhibitory Polypeptide Receptor Market Facts & Figures by Country
- 5.7.1 South America Gastric Inhibitory Polypeptide Receptor Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Gastric Inhibitory Polypeptide Receptor Sales by Country (2021-2032)
- 5.7.3 South America Gastric Inhibitory Polypeptide Receptor Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Gastric Inhibitory Polypeptide Receptor Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Gastric Inhibitory Polypeptide Receptor Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Gastric Inhibitory Polypeptide Receptor Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Gastric Inhibitory Polypeptide Receptor Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Gastric Inhibitory Polypeptide Receptor Sales by Type (2021-2032)
- 6.1.1 Global Gastric Inhibitory Polypeptide Receptor Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Type (2021-2032)
- 6.2 Global Gastric Inhibitory Polypeptide Receptor Revenue by Type (2021-2032)
- 6.2.1 Global Gastric Inhibitory Polypeptide Receptor Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Type (2021-2032)
- 6.3 Global Gastric Inhibitory Polypeptide Receptor Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Gastric Inhibitory Polypeptide Receptor Sales by Application (2021-2032)
- 7.1.1 Global Gastric Inhibitory Polypeptide Receptor Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Application (2021-2032)
- 7.2 Global Gastric Inhibitory Polypeptide Receptor Revenue by Application (2021-2032)
- 7.2.1 Global Gastric Inhibitory Polypeptide Receptor Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Application (2021-2032)
- 7.3 Global Gastric Inhibitory Polypeptide Receptor Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Gastric Inhibitory Polypeptide Receptor Value Chain Analysis
- 8.1.1 Gastric Inhibitory Polypeptide Receptor Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Gastric Inhibitory Polypeptide Receptor Production Mode & Process
- 8.2 Gastric Inhibitory Polypeptide Receptor Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Gastric Inhibitory Polypeptide Receptor Distributors
- 8.2.3 Gastric Inhibitory Polypeptide Receptor Customers
9 Global Gastric Inhibitory Polypeptide Receptor Analyzing Market Dynamics
- 9.1 Gastric Inhibitory Polypeptide Receptor Industry Trends
- 9.2 Gastric Inhibitory Polypeptide Receptor Industry Drivers
- 9.3 Gastric Inhibitory Polypeptide Receptor Industry Opportunities and Challenges
- 9.4 Gastric Inhibitory Polypeptide Receptor Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst